𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevention of clinical events and restenosis after percutaneous transluminal coronary angioplasty with trapidil: results of the STARC II study

✍ Scribed by Aleardo Maresta; Marco Balducelli; Spencer B. King III; Roberto Latini; Tiziano Moccetti; Alessandro Monici-Preti; Elisabetta Varani; Aldo P. Maggioni

Book ID
119543725
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
141 KB
Volume
39
Category
Article
ISSN
1558-3597

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Starc II, a multicenter randomized place
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting
✍ Aleardo Maresta; M. Balducelli; R. Latini; G. Bernardi; T. Moccetti; C. Sosa; S. πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 93 KB πŸ‘ 1 views

## Abstract The objective of this study was to investigate the effect of trapidil 200 mg t.i.d. in preventing the occurrence of death, of myocardial infarction and the need for repeat revascularization at 12 months after balloon PTCA with or without stenting. Coronary restenosis after stenting is s

Restenosis, reocclusion and adverse card
Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries: Results from the multicenter american research trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (MARCATOR)
✍ Peter B. Berger; David R. Holmes Jr.; E. Magnus Ohman; Mary Ann O'Hanesian; Jose πŸ“‚ Article πŸ“… 1996 πŸ› Elsevier Science 🌐 English βš– 674 KB